ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Arrowhead Pharmaceuticals and Eli Lilly side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Arrowhead PharmaceuticalsEli Lilly
studies on the registry512,262
open to participants now8173
phase 3 studies under way4104
reach primary completion within a year6104
programswith a study of their own in two years893+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseArrowhead PharmaceuticalsEli Lilly
Phase 1

Arrowhead Pharmaceuticals: 1 of its 8 programs at phase 1

  1. ARO-033phase 1
13%

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%
Phase 2

Arrowhead Pharmaceuticals: 5 of its 8 programs at phase 2

  1. ARO-INHBEphase 2
  2. ARO-RAGEphase 2
  3. ARO-ALK7phase 2
  4. ARO-DIMERPAphase 2
  5. ARO-MAPT-SCphase 2
63%

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
Phase 3

Arrowhead Pharmaceuticals: 2 of its 8 programs at phase 3

  1. plozasiranphase 3
  2. zodasiranphase 3
25%

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%
Approved, new studies00%

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Arrowhead Pharmaceuticals5 readouts · 1 phase 3···

Arrowhead Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion

  1. ARO-ALK7phase 2 · Feb 0 · NCT06937203
···

Arrowhead Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. ARO-MAPT-SCphase 2 · Jun 0 · NCT07221344

Arrowhead Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. ARO-DIMERPAphase 2 · Jul 0 · NCT07223658

Arrowhead Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zodasiranphase 3 · Aug 20 · NCT07037771
·

Arrowhead Pharmaceuticals, Oct ’27: 1 program whose next study reaches primary completion

  1. ARO-INHBEphase 2 · Oct 15 · NCT06700538
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Arrowhead Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionArrowhead PharmaceuticalsEli Lilly
Obesityboth · compare here

Arrowhead Pharmaceuticals in Obesity: 2 programs

  1. ARO-INHBEphase 2
  2. ARO-ALK7phase 2

Their studies: Arrowhead Pharmaceuticals’ studies of Obesity in search

Eli Lilly in Obesity: 18 programs

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. macupatidephase 2

and 13 more — sign in to see them all

Their studies: Eli Lilly’s studies of Obesity in search

Alzheimer Diseaseboth · compare here

Arrowhead Pharmaceuticals in Alzheimer Disease: 1 program

  1. ARO-MAPT-SCphase 2

Their studies: Arrowhead Pharmaceuticals’ studies of Alzheimer Disease in search

Eli Lilly in Alzheimer Disease: 5 programs

  1. remternetugphase 3
  2. LY4405094phase 1
  3. LY3439539phase 1
  4. LY4560736phase 1
  5. donanemabapproved, new study

Their studies: Eli Lilly’s studies of Alzheimer Disease in search

Asthmaboth · compare here

Arrowhead Pharmaceuticals in Asthma: 1 program

  1. ARO-RAGEphase 2

Their studies: Arrowhead Pharmaceuticals’ studies of Asthma in search

Eli Lilly in Asthma: 2 programs

  1. brenipatidephase 3
  2. lebrikizumabapproved, new study

Their studies: Eli Lilly’s studies of Asthma in search

Dyslipidemiasboth · compare here

Arrowhead Pharmaceuticals in Dyslipidemias: 2 programs

  1. plozasiranphase 3
  2. zodasiranphase 3

Their studies: Arrowhead Pharmaceuticals’ studies of Dyslipidemias in search

Eli Lilly in Dyslipidemias: 1 program

  1. solbinsiranphase 2

Their studies: Eli Lilly’s studies of Dyslipidemias in search

Fatty Liverboth · compare here

Arrowhead Pharmaceuticals in Fatty Liver: 1 program

  1. ARO-INHBEphase 2

Their studies: Arrowhead Pharmaceuticals’ studies of Fatty Liver in search

Eli Lilly in Fatty Liver: 1 program

  1. mazdutidephase 2

Their studies: Eli Lilly’s studies of Fatty Liver in search

Hyperlipoproteinemia Type IIboth · compare here

Arrowhead Pharmaceuticals in Hyperlipoproteinemia Type II: 1 program

  1. ARO-DIMERPAphase 2

Their studies: Arrowhead Pharmaceuticals’ studies of Hyperlipoproteinemia Type II in search

Eli Lilly in Hyperlipoproteinemia Type II: 1 program

  1. VERVE-102phase 2

Their studies: Eli Lilly’s studies of Hyperlipoproteinemia Type II in search

Hypertriglyceridemiaboth · compare here

Arrowhead Pharmaceuticals in Hypertriglyceridemia: 1 program

  1. plozasiranphase 3

Their studies: Arrowhead Pharmaceuticals’ studies of Hypertriglyceridemia in search

Eli Lilly in Hypertriglyceridemia: 1 program

  1. solbinsiranphase 2

Their studies: Eli Lilly’s studies of Hypertriglyceridemia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Arrowhead Pharmaceuticals 0 of 8 · Eli Lilly 50 of 93 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).